Abstract: To the Editors: Adults with schizophrenia have higher rates of smoking and nicotine dependence and lower rates of smoking cessation than other adults (1-3). Further, the medical and economic burden of smoking on mentally ill persons is enormous (3, 4) so the development of safe and effective pharmacotherapies for these smokers is of considerable public health significance. FDA-approved smoking cessation pharmacotherapies like nicotine replacement therapy (NRT) and sustained-release bupropion (Zyban®, GlaxoSmithKline) appear to be safe and effi...
(read more)
Topics: 
Psychiatry
Clinical psychology